Ran Nakashima

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Hideaki Tsuji, Ran Nakashima, Yuji Hosono et al. · Arthritis & Rheumatology · 2019 · 344 citations · Full text

The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody

Ran Nakashima, Yoshitaka Imura, Shio Kobayashi et al. · Lara D. Veeken · 2009 · 329 citations

Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis

Kei Hoshino, Yoshinao Muro, Kazumitsu Sugiura et al. · Lara D. Veeken · 2010 · 256 citations

Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease

Hironao Hozumi, Tomoyuki Fujisawa, Ran Nakashima et al. · Respiratory Medicine · 2016 · 181 citations · Full text

Rheumatology, Comprehensive Assessment, Autoimmune Disease +8

HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody

Kiminobu Tanizawa, Tomohiro Handa, Ran Nakashima et al. · Respiratory Medicine · 2011 · 137 citations

Clinical Immunology, Autoimmune Disease, Medicine +9